

## **CLINICAL INSIGHTS**

## **BLUE CROSS Division of Blue Cross Laboratories**

## **OMEPREN TABLETS**

Issue VI, No.19, 2024

Efficacy and Safety of Omeprazole for the Treatment of Acid peptic Disorders: A Systemic Review and Meta-Analysis

Prasad VG, et al. Int. J. Clin. Pract. 2024

- In India, Omeprazole is the only oral proton pump inhibitor (PPI) listed in the National List of Essential Medicines.
- The current study analyzed 31 trials (10,539 patients) to compare the efficacy of Omeprazole to other PPIs for the treatment of acid peptic disorders (APDs).
- Omeprazole significantly improved heartburn, was more effective for the overall improvement of APD symptoms compared to placebo (p < 0.001) and was equivalent to the other PPIs (Esomeprazole, Ilaprazole, Lansoprazole, Pantoprazole and Rabeprazole) studied.
- Omeprazole was associated with significantly fewer adverse events compared to placebo and other PPIs and was the most cost-effective compared to the other types of PPIs in India.

Omeprazole continues to be an effective proton pump inhibitor for acid peptic disorders and is well tolerated.

**\*\*\*\***